Appropriately timed proliferation, differentiation and apoptosis are essential to the normal functions of the mammary epithelium. Here, we report that the transcription factor BCL-6 is expressed in mammary epithelium in nonpregnant animals as well as during early pregnancy. When overexpressed in the nontransformed EpH4 mammary epithelial cell line, BCL-6 prevents the STAT-driven expression of the milk protein b-casein and duct formation, and prevents apoptosis. Consistent with an antiapoptotic function, we demonstrate that BCL-6 is expressed in 68% of histologically high-grade ductal breast carcinomas, which are clinically the most aggressive. BCL-6 has previously been characterized as a regulator of B lymphocyte growth and development, but our work identifies a novel role for it in mammary epithelial differentiation, which may also implicate it in carcinogenesis.
Introduction
Mammary epithelium comprises a ductal component, which develops during puberty, and a secretory lobuloalveolar component, which develops in pregnancy and is maintained during lactation. The regulation of this epithelium requires the orchestration of proliferation, differentiation and apoptosis. These processes are driven by a combination of hormonal signals and signals from components of the extracellular matrix as well as external signals such as suckling, which promotes lactation, and milk stasis within the mammary gland ducts on weaning, which promotes involution. Of the many signalling pathways involved in mammary epithelial development, the signal transducers and activators of transcription (STAT) family of transcription factors are particularly important. STAT5 is activated transiently during estrus (Liu et al., 1996) , and to a much greater extent during pregnancy and lactation, and is involved in proliferation and differentiation at these times. However, remodelling of the mammary gland and epithelial cell death which occurs during involution at the time of weaning is mediated by STAT3.
The lymph node germinal centre is apparently an entirely different environment from that of mammary epithelium, in which B lymphocytes proliferate and are selected for the production of high-affinity antibodies before becoming either terminally differentiated plasma cells or memory cells. In part, these processes are controlled by interleukins that activate STATs through interleukin receptors on the B-cell surface. Our previous work, and that of others (Reljic et al., 2000; Shaffer et al., 2000) , has demonstrated that the zinc-finger transcription factor BCL-6, which is highly expressed in germinal centre B cells, can arrest B-cell terminal differentiation.
BCL-6 was first cloned from a chromosomal translocation in a human B-cell lymphoma (Ye et al., 1993) . Its N-terminal POZ domain is able to recruit corepressor molecules and histone deacetylase and thereby mediate transcriptional repression (Chang et al., 1996) . BCL-6 has an essential role in the normal acquired humoral immune response as demonstrated by the lack of germinal centres in mice bearing homozygous disruptions of this gene (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997) .
The DNA-binding sequence of BCL-6 conforms to the STAT family consensus-binding sequence (Dent et al., 1997) , and BCL-6 has subsequently been shown to bind with varying affinities to different STAT sites (Harris et al., 1999) . A likely mechanism of action of BCL-6 is modulation of the effects of STATs by binding (and so competing) with differing affinities to different STAT target sequences. Such a role may be particularly important in situations in which STATs are responsible for driving conflicting biological processes, for example proliferation and differentiation. In such cases, BCL-6 may act as a filter such that those STAT effects that cause proliferation are permitted but those that cause differentiation are inhibited.
BCL-6 protein expression has been found in sites outside the lymphoid system. It is expressed in various epithelial sites in the mouse embryo and in the olfactory bulb (Bajalica-Lagerkrantz et al., 1998) . It is also found in the keratinocytes of mature animals and BCL-6 expression is associated with terminal differentiation of this cell type (Yoshida et al., 1996) . Furthermore, BCL-6 is expressed in various skin tumours (Kanazawa et al., 1997) . Human breast epithelium EST libraries as well as libraries obtained from other epithelial tissues, for example, ovarian, contain low numbers of BCL-6 transcripts, and gene expression profiling has demonstrated BCL-6 to be present in breast cancers (van't Veer et al., 2002) , although nothing is known of protein expression either in normal tissues or cancers. The function of BCL-6 in mammary epithelium has also not been addressed. In this report, we show that BCL-6 is expressed in mammary epithelium and suggest that it forms part of a system for maintaining cell viability and replicative potential, and preventing differentiation.
Results

BCL-6 expression in mouse mammary epithelium and the EpH4 cell line
BCL-6 protein expression was assessed by immunohistochemistry. Staining was present in 5-10% of epithelial cells in nonpregnant and early pregnant animals, but was not detectable at later stages of development ( Figure 1a) .
Based on previous work on B cells (Reljic et al., 2000; Shaffer et al., 2000) , we surmised that BCL-6 is involved in the control of growth and differentiation of mammary epithelium. We chose to approach this problem by utilizing a nontumour cell line -EpH4 -derived from mammary epithelium. This cell line is able to differentiate in response to lactogenic hormones and extracellular matrix, by two measures: firstly, production of the milk protein b-casein and secondly, formation of ductal or alveolar structures (Niemann et al., 1998) . EpH4 is, therefore, highly suitable for the purpose of exploring the effects of molecules that disrupt differentiation, both because it maintains a requirement for stromal as well as hormonal signals and because differentiation can be assessed by more than one criterion. While BCL-6 mRNA was weakly detectable on Northern blot (Figure 1b) , protein expression was undetectable (Figure 1c) . The discordance between BCL-6 mRNA and protein levels (Allman et al., 1996) may be due to post-translational modification (Niu et al., 1998) leading to proteasomal degradation. However, this is unlikely to be the only mechanism for the control of BCL-6 and indeed, as compared to A20 cells (a mouse B cell line in which both BCL-6 mRNA and protein are expressed), there is relatively little mRNA in EpH4. There may therefore be both transcriptional and posttranscriptional controls operating on BCL-6 in EpH4 under basal conditions. However, although mRNA levels of BCL-6 increased in EpH4 in response to lactogenic hormones and ECM (Figure 1d ), there was no corresponding alteration in protein expression (Figure 1e ), which remained undetectable. Under conditions in which differentiation is induced, post-transcriptional mechanisms controlling BCL-6 protein levels may be operating, with the result that there is little or no BCL-6 protein expressed.
Functional effect of BCL-6 on EpH4 differentiation
In order to analyse the effect of BCL-6, two retrovirally transduced EpH4 cell lines were produced, one bearing (Reljic et al., 2000) . The BCL-6 utilized in this work has been mutated at two serine residues (333 and 343) in order to prolong the half-life of the protein and so optimize its functional effects (Niu et al., 1998) . After purification by flow sorting, BCL-6 protein levels were found to be comparable to those of A20 cells (Figure 2) .
A property of EpH4 cells is the formation of ductal or alveolar structures when grown on Engelbreth-HolmSwarm-derived extra-cellular-matrix (EHS-ECM) in the presence of hepatocyte growth factor/scatter factor (HGF/SF) (Niemann et al., 1998) , a molecule which can both mediate STAT3 transcription (Boccaccio et al., 1998) and modulate integrin signalling (Trusolino et al., 2001) . In our hands, HGF/SF caused control EpH4 cells to form large loculated structures, but BCL-6 prevented this effect (Figure 3a) , and the cells tended to form small clusters. Overall, cell clusters produced by pHL6-BCL6-transduced EpH4 contained no multiloculated forms and only a few forms with a single cavity (Figure 3b) , and with virtually none of the central excavation seen in the control cells.
b-Casein expression was utilized as a measure of biochemical differentiation. RT-PCR, (Figure 4a ) suggests that BCL-6 was able to partially prevent b-casein production. This was further investigated by means of transient transfection assays in which a luciferase gene was placed under the control of a segment of the human b-casein promoter, which has been previously established to respond to prolactin and hydrocortisone (Winklehner-Jennewein et al., 1998) largely through STAT5-binding sites. There was a modest increase in luciferase activity in the control cells, comparable to levels obtained by others (Winklehner-Jennewein et al., 1998) , but this was abrogated in EpH4 cells in which BCL-6 was constitutively active (Figure 4b ). BCL-6 can bind to a variety of STAT sites including those of STAT6 (Dent et al., 1997; Harris et al., 1999) and STAT3 (Reljic et al., 2000) . Gel-shift assays were carried out in order to find out if the effect of BCL-6 was direct, that is, due to binding to any of the three STAT5 sites within the experimentally used promoter element, or indirect, that is, no binding. These show that BCL-6 binds to one of the previously identified STAT5 sites (S1) (Figure 4c ), but not to the other two sites, consistent with the luciferase results. This binding was confirmed to be due to BCL-6 by antibody supershift and was specific as demonstrated by competition with unlabelled S1 oligonucleotide. The core sequence of the S1 STATS site (TTCTAAGAA) is identical to the core sequence of a STAT6-binding site in the CD23 promoter which is a target for BCL-6 (Dent et al., 1997) . This illustrates the potentially complex nature of the binding of STAT family proteins to DNA, and supports a function for BCL-6 as a modulator of b-casein transcription.
Effects of BCL-6 on growth and apoptosis of EpH4 cells
Next, the effects of BCL-6 on growth of EpH4 cells were characterized. As anticipated, BCL-6 expression was associated with a small increase in the number of cells in S phase of the cell cycle as assessed by the incorporation of the pyrimidine analogue BrdU (Figure 5a) . In order to induce differentiation, cells are BCL-6 prevention of mammary epithelial differentiation S Logarajah et al grown in serum-free medium, and under such conditions, it is unlikely that large proliferative responses will be observed. However, BCL-6 was able to partially prevent apoptosis when cells were cultured in differentiation medium (Figure 5b ).
BCL-6 expression in breast cancer
The role of BCL-6 in allowing proliferation (or preventing apoptosis) suggested that it may be expressed in cases of human breast cancer. Initial staining of normal human tissue showed BCL-6 expression in a minority (5-10%) of epithelial cells similar to our findings in nonpregnant and early pregnant mouse mammary glands (Figure 6a ). There was no staining of myoepithelial cells. Areas of apocrine metaplasia, whose significance is unclear, stained uniformly for BCL-6. Oestrogen receptor (ER) positivity is correlated with proliferation of normal epithelial cells, as is Ki-67 positivity, but these two markers stain separate populations of cells. BCL-6 staining did not segregate absolutely either with ER positivity or with Ki-67 positivity, although there is an overlap such that a proportion of epithelial cells are positive for both BCL-6 and ER whereas others express BCL-6 with Ki-67. Such results are compatible with the hypothesis that BCL-6 expression correlates with proliferation. Breast cancer cases were subdivided histologically into grades 1-3, of which grade 1 is the least and grade 3 the most clinically aggressive. Of 93 assessable breast cancer cases, 14 were There is specific binding (indicated by the arrow labelled s) to probe S1, and nonspecific binding (ns) to probe S2. The unlabelled arrow indicates the origin. Supershift experiments were carried out using 2 and 5 mg of rabbit polyclonal anti-BCL-6 (N3) (Santa Cruz) and cold competition studies employed 1, 5 and 10 pmol of unlabelled S1 (Figures  6b and c) . Western analysis of a case of breast cancer was carried out to confirm that a protein of the molecular weight expected for BCL-6 was present (Figure 6d ). BCL-6 is, therefore, expressed within a subgroup of high-grade ductal carcinomas.
Discussion
BCL-6 inhibits the differentiation of a mouse B-cell lymphoma cell line (Reljic et al., 2000) , a function which is supported by microarray studies (Shaffer et al., 2000) . Furthermore, BCL-6-transfected mouse splenocytes (Reljic et al., 2000) and human tonsillar cells (Shvarts et al., 2002) continue to proliferate under conditions in which normal cells die. This transcription factor can, therefore, control key aspects of cellular development, and it may exert its effects by modulating STAT signalling (Dent et al., 1997; Harris et al., 1999; Reljic et al., 2000) . However, BCL-6 transcripts are present in EST libraries from normal breast tissue and because of the importance of STAT signalling in this situation, we sought a role for it in mammary epithelium and also expression in breast cancer. Our results demonstrate that in both man and mouse, BCL-6 is expressed in 10-20% of epithelial cells in the nonpregnant mammary gland. One hypothesis, advanced as a result of the finding that BCL-6 disrupts terminal differentiation in a model B-cell system, is that this transcription factor acts as a filter that allows STAT-driven proliferation, but prevents differentiation, which may be mediated by other members of the STAT family (Reljic et al., 2000) . There is transient activation of STAT5 in nonpregnant animals during oestrus (Liu et al., 1996) and BCL-6 may maintain replicative potential within a subpopulation of mammary epithelial cells by completely or partially inhibiting this transcription factor. The cell-surface ER and the nuclear antigen Ki-67 are known to be associated with proliferation of normal mammary epithelium. There is only partial overlap of expression between ER and Ki-67 and BCL-6. One possibility is that BCL-6 promotes cell-cycle progression by upregulating cyclin D1 (Shvarts et al., 2002) , a protein which is overexpressed in breast cancer cell lines and primary tissue (Buckley et al., 1993; Bartkova et al., 1994) .
A model such as the one outlined above permits both continuing cell growth and differentiation to occur, but in separate cell populations. This allows resolution of the paradox that BCL-6 is expressed in mammary epithelium while differentiation occurs, although its expression must cease before B cells can differentiate to plasma cells For B cells, growth in the germinal centre and differentiation with the development of effector function are spatially and temporally separate, but this division is not distinct in epithelial tissues where proliferating cells may be adjacent to differentiated cells. It is generally true that cellular differentiation is linked to a reduction in replicative potential and ultimately apoptotic cell death. The finding that the human programmed cell death-2 (PDCD2) gene is a target for BCL-6 repression (Baron et al., 2002) provides support for the concept that it is antiapoptotic. Overall, despite work which shows that BCL-6 is proapoptotic (Tang et al., 2002) , this transcription factor appears to be associated with continuing replicative potential and growth and its absence allows terminal differentiation and death by apoptosis. Our results demonstrate that the function of BCL-6 in mammary epithelium, a tissue in which its function has not previously been explored, is compatible with these concepts.
Cytogenetic studies have not implicated BCL-6 in chromosomal translocations in breast cancers. Mutations or deletions of a putative intronic silencer have been proposed to cause BCL-6 overexpression in some cases of lymphoma and this mechanism may also be important in breast cancers. BCL-6 is expressed predominantly in high-grade cancers and it may Although our results suggest a role for BCL-6 in the maintenance of viability of the mammary epithelium, it is puzzling that mice bearing homozygous disruptions of the BCL-6 locus do not have prominent abnormalities of mammary gland development. There are several possibilities. Firstly, it is not clear whether any of these animals became pregnant as a majority were severely ill, with 50% dying before they were 5 weeks old (Dent et al., 1997) . Secondly, BCL-6 may have a nonessential role in vivo with other molecules, possibly Id1 (Desprez et al., 1995) or Id2 (Mori et al., 2000) , being able to substitute for it. In such a scenario, pregnant mice kept in animal house conditions might have only a subtle phenotype displaying more apoptosis than normal and exhibiting unduly rapid involution. However, some predictions of the in vivo effects of overexpression of BCL-6 in mammary epithelium follow from the results reported here. Firstly, constitutive expression of BCL-6 may prevent mammary epithelial differentiation as assessed by expression of milk proteins, and secondly the maintenance of replicative potential caused by BCL-6 may predispose to the formation of breast cancers.
Overall, our results suggest that BCL-6 prevents terminal differentiation, maintains replicative potential and prevents apoptosis of mammary epithelium during the development and maturation of the mammary epithelium. There are parallels between this outline of the function of BCL-6 in mammary epithelium and its function in B-cell development.
Materials and methods
Cell culture and differentiation
EpH4 cells (3.5 Â 10 5 ) (gift of Dr W Birchmeier, Berlin) were employed in differentiation assays as described (Niemann et al., 1998) . Cells were plated on EHS-ECM-(Sigma) coated dishes in serum-free medium with 3 mg/ml prolactin (Sigma), 1 mg/ml hydrocortisone (Sigma) and 5 mg/ml insulin (Sigma). Recombinant mouse HGF/SF (gift of Dr E Gherardi, Cambridge) was used at 20 ng/ml.
Retroviral transduction
Full-length BCL-6 cDNA containing mutations at residues 333 and 343 was cloned into a Moloney murine leukaemia virus-based vector (Reljic et al., 2000) and viral supernatant was produced by calcium phosphate transfection of the Phoenix packaging cell line. Cells expressing GFP were flow sorted (FACSVantage, Becton Dickinson).
Immunohistochemistry
Duplicate tissue array slides for lobular and ductal carcinomas were utilized. Two tissue arrays comprising 151 breast cancers were used to investigate the role of the BCL-6 protein in breast cancer. Owing to dropout of the tissue cores, 93 were available for assessment.
Mouse mammary glands were dissected from 6-week-old nonpregnant CBA/CH57-BL6 (F1) mice as well as at midpregnancy (day 12), lactation (day 7) and involution (day 1). The sections were dewaxed in xylene and rehydrated in alcohol. Antigen retrieval was carried out using high-temperature unmasking technique with diaminobenzidine chromagen solution (DAKO) high pH target retrieval solution in the microwave. Sections were quenched with peroxidase block (from DAKO EnVision þ kit) for 5 min. Immunostaining was carried out using the two-step DAKO EnVision þ staining system. Sections were incubated with the monoclonal anti-BCL 6 antibody (DAKO) (1/10 dilution in TBS) for 45 min, rinsed with TBS/Tween buffer followed by incubation with the HRP-labelled polymer for 45 min. Visualization was with DAKO for 10 min at room temperature. Counterstaining with Harris's haematoxylin was carried out on the LEICA XL Autostainer.
Flow cytometry
10
6 cells were washed in PBS and plated in 10 ml of DMEM without serum and with 1% EHS-ECM (Muschler et al., 1999) , together with other additives as described above, for 24 h. The medium was then replaced by DMEM with additives as above and 10 mm BrdU (Sigma). After a further 24 h, the cells were removed with trypsin, washed in PBS, fixed with 1% paraformaldehyde for 20 min and then permeabilized with 0.1% saponin in PBS containing 4% FCS. Cells were digested with DNase (Invitrogen) for 1 h at 371C and after washing and incubation with PE-conjugated anti-BrdU (Pharmingen), the proportion of positive cells was measured on a FACScalibur machine (Becton-Dickinson). In order to assess apoptosis, 10 6 cells were plated under conditions that induce differentiation (DMEM without serum and with additives as above, for the times indicated). Cells were removed with trypsin and stained with PE-conjugated anti-annexin V (Pharmingen) according to the manufacturer's instructions.
Luciferase assays
10
6 cells were cotransfected, using Lipofectamine (Invitrogen), with 10 mg of a firefly luciferase reporter construct bearing 380 bp of the human b-casein promoter (positions À4729 to À4340), which had previously been identified as containing STAT sites that confer prolactin inducible transcription (Winklehner-Jennewein et al., 1998) , and 0.5 mg of a Renilla luciferase control vector (Promega). Cells were removed after 24 h in differentiation medium and lysed in 50 ml of passive lysis buffer by three freeze/thaw cycles. Firefly luciferase and Renilla luciferase were measured by the use of a Dual Luciferase Reporter Kit (Promega) and a Turner Instruments TD20 luminometer. Protein concentration was measured by BCA assay (Pierce).
EMSA
Full-length BCL-6 cloned into pTnT vector (1 mg) (Promega) was used in a cell-free wheatgerm-coupled transcription/ translation system (Promega) containing 50 mm zinc chloride. Probes derived from the three STAT sites in the human bcasein promoter (S1-5 0 aagcatttttctaagaaaaaacaaa, S2-5 0 gtattactttcttagaaaccttaac and S3-5 0 cctgggttttctgagaaatatgaaa) (Winklehner-Jennewein et al., 1998) were end labelled with T4 polynucleotide kinase. Each probe (1 00 000 c.p.m.) was mixed with 2 ml of in vitro translated material in 20 mm HEPES buffer (pH 7.5), 50 mm KCl, 1 mm MgCl 2 , 10 mm ZnCl 2 and 4% glycerol containing 1 mg polydIdC, for 15 min at room temperature and then run on a 4% polyacrylamide gel containing 5% glycerol.
